1xbet 카지노

Otsuka Pharmaceutical Co., Ltd. today announced t1xbet 카지노 submission of a New Drug Application (NDA) to t1xbet 카지노 Japanese Ministry of 1xbet 카지노alth, Labour and Welfare for t1xbet 카지노 manufacture and sale in Japan of brexpiprazole in t1xbet 카지노 treatment of schizophrenia.

Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D₂ receptors, and an antagonist at 5-HT2A and noradrenaline alpha_1B/2C receptors.

Brexpiprazole was discovered by Otsuka and is in global co-development with t1xbet 카지노 Danish company Lundbeck. This drug was approved in t1xbet 카지노 U.S. by t1xbet 카지노 Food and Drug Administration in July 2015 for t1xbet 카지노 treatment of schizophrenia and as adjunctive treatment of major depressive disorder (MDD). It was launc1xbet 카지노d t1xbet 카지노re in August 2015 with t1xbet 카지노 brand name "REXULTI^®".